Erin Krikie
Psychiatric/Mental Health · Eldorado, ILNPI 1447618897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$738
- Johnson & Johnson$719
- Otsuka America Pharmaceutical, Inc.$600
- AbbVie$498
- Teva Pharmaceuticals USA, Inc.$479
- Vanda Pharmaceuticals Inc.$413
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,26797%
- Education$1423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 46 | $738 |
| Johnson & Johnson | 53 | $719 |
| Otsuka America Pharmaceutical, Inc. | 55 | $600 |
| AbbVie | 43 | $498 |
| Teva Pharmaceuticals USA, Inc. | 36 | $479 |
| Vanda Pharmaceuticals Inc. | 20 | $413 |
| Neurocrine Biosciences, Inc. | 17 | $311 |
| Axsome Therapeutics, Inc. | 10 | $251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $226 |
| Dexcom, Inc. | 9 | $155 |
| Gilead | 8 | $144 |
| Lundbeck LLC | 8 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Xeris Pharmaceuticals, Inc. | 3 | $69 |
| Braeburn Inc. | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 6 | $57 |
| Indivior Inc. | 3 | $55 |
| USWM, LLC | 3 | $51 |
| Merck | 2 | $45 |
| Lilly USA, LLC | 2 | $36 |
| Novo Nordisk | 1 | $24 |
| Eisai Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,408 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 31 | $108,940 |
| IngrezzaValbenazine Tosylate | 13 | $106,888 |
| RexultiBrexpiprazole | 69 | $104,430 |
| VraylarCariprazine Hcl | 55 | $83,851 |
| TrintellixVortioxetine Hydrobromide | 124 | $59,511 |
| SpravatoEsketamine Hcl | 27 | $29,522 |
| Lurasidone Hcl | 98 | $28,878 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,005 |
| Paliperidone ErPaliperidone | 28 | $6,612 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $6,069 |
| Quetiapine Fumarate | 371 | $5,634 |
| Rivastigmine | 23 | $4,704 |
| Aripiprazole | 97 | $4,600 |
| Lisdexamfetamine Dimesylate | 19 | $3,645 |
| Buspirone Hcl | 236 | $2,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato | $719 | $138,46258 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $311 | $106,88813 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $600 | $104,43069 claims |
| AbbVieVraylar | $498 | $83,85155 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $129 | $68,516148 claims |
| Axsome Therapeutics, Inc.Auvelity | $251 | $6,06912 claims |
| Lilly USA, LLCOlanzapine | $36 | $1,22058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Eldorado
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.